News

News Archive

  • 12.07.2017  |  Vedanta announces start of Phase 1a/1b, first-in-human, clinical trial of VE303, an oral microbiome therapeutic for the treatment of recurrent C. difficile infections

    BUSINESS WIRE | Vedanta’s VE303, a Powered by CARB-X project, is the first known investigational drug consisting of a rationally-defined bacterial consortium in powder form to enter the clinic. VE303 granted Orphan Drug Designation by the FDA. Business Wire, December 7, 2017

    Full Story

  • 12.06.2017  |  New Antibiotic Action

    SCIENCE | Commentary on new agents to treat gram-negative bacterial infections

    Full Story

  • 11.30.2017  |  EligoChem Ltd., a Powered by CARB-X company, teams up with UK’s AMR Centre to focus on development of antimicrobial peptides

    SELECT SCIENCE | AMR Centre are taking on an early stage programme with EligoChem to combat antimicrobial resistance

    Full Story

  • 11.22.2017  |  Powered by CARB-X partner Bugworks and other companies fighting back against India’s looming drug-resistance crisis

    BBC | Bugworks has high-profile support after becoming the first company outside the US or Europe funded by the $455m (£343m) CARB-X accelerator, which supports start-ups combating antimicrobial-resistance (AMR)

    Full Story

  • 11.22.2017  |  Interview with CARB-X Executive Director Kevin Outterson on how the CARB-X model is accelerating antibacterial innovation

    PHARMACEUTICAL TECHNOLOGY | Resistance to antibiotics is rising but the business model for developing new antibiotic drugs is broken. Could CARB-X, the world’s largest public-private partnership devoted to antibacterial research and development, be the answer?

    Full Story

  • 11.21.2017  |  Antimicrobial resistance: An underrated biological threat

    BULLETIN OF THE ATOMIC SCIENTISTS | Alexander Fleming, who discovered penicillin, predicted an age when the efficacy of antibiotics would diminish and wither away.

    Full Story

  • 11.15.2017  |  Proteus gets helping hand from CLSI to transform itself from a research consortium into a VC-backed entity

    CLSI | Proteus, a research consortium based in Edinburgh, Scotland, and backed by CARB-X, got a welcome crash course from CARB-X partner California Life Science Institute on becoming a venture-capital-backed entity

    Full Story

  • 10.30.2017  |  Preclinical antibiotic pipeline gets a pick-me-up

    NATURE REVIEWS DRUG DISCOVERY | CARB-X is giving the global pre-clinical antibiotic pipeline a badly needed boost with critical support and exciting projects

    Full Story

  • 10.26.2017  |  Why it is so difficult to develop new antibiotics? A look at the scientific challenges and broken economic model of R&D work, by Tim Jinks of Wellcome Trust

    BBC | Over-reliance on and misuse of antibiotics has led to warnings of a future without effective medicines.

    Full Story

  • 10.16.2017  |  Antabio, a Powered by CARB-X company developing Pseudomonas elastase inhibitors, raises 7.3 million Euros in a first round of Series A financing

    ANABIO | This financing complements the recent CARB-X grant of up to $8,9 million awarded to Antabio in July 2017 to support the company’s Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.

    Full Story

  • 10.06.2017  |  Market watch: Innovation in the preclinical antibiotic pipeline

    NATURE REVIEWS DRUG DISCOVERY | Analysis of CARB-X portfolio shows strong diversity and promise but high attrition rates for innovation suggest more incentives and support are needed to maintain positive momentum toward clinical trials.

    Full Story

  • 09.25.2017  |  Report highlights progress made in global AMR fight

    CIDRAP | A new report from the United Nations Foundation and the Wellcome Trust is highlighting the progress that's been made, and the work that needs to be done, in the year since world leaders made a commitment to address antimicrobial resistance (AMR).

    Full Story

  • 09.21.2017  |  Sustaining Global Action on Antimicrobial Resistance: A report on global progress published by Wellcome Trust and the United Nations Foundation

    WELLCOME TRUST | Report

    Full Story

  • 09.04.2017  |  Proteus, Powered by CARB-X partner, reports breakthrough imaging technology

    PROTEUS | Imaging technology allows doctors to see instruments inside the boduy during medical procedures.

    Full Story

  • 07.25.2017  |  CARB-X awards $17.6 million to fund new antibiotic development

    CIDRAP | Funds for antibiotic development; Improper antibiotic prescribing.

    Full Story

  • 07.25.2017  |  CARB-X awards $17.6M in grants to support global antibiotic development projects

    Genetic Engineering and Biotechnology News

    Full Story

    Full Story

  • 03.30.2017  |  US-UK alliance targets the world’s deadliest superbugs

    US News and World Report

    Full Story

    Full Story

  • 03.30.2017  |  Lung probe ‘to help cut the unnecessary use of antibiotics’

    BBC

    Full Story

    Full Story

  • 03.30.2017  |  Quest for new antibiotics gets first major funding from global partnership

    A major global partnership aimed at fighting superbugs announced Thursday that it is investing up to $48 million in research projects, including potentially the first new classes of antibiotics in decades, to target the deadliest drug-resistant bacteria. Washington Post

    Full Story

    Full Story